Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells

Melinda A. Biernacki, Ovidiu Marina, Wandi Zhang, Fenglong Liu, Ingmar Bruns, Ann Cai, Donna Neuberg, Christine M. Canning, Edwin P. Alyea, Robert J. Soiffer, Vladimir Brusic, Jerome Ritz, Catherine J. Wu

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) may result from immunologic ablation of self-renewing CML progenitor cells. Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in patients who were unresponsive to DLI. In this study, we identified antigen targets of this B-cell response by probing two immunoproteomic platforms with plasma immunoglobulins from seven CML patients with clinically apparent graft-versus-leukemia responses after DLI. In total, 62 antigens elicited greater reactivity from post-DLI versus pre-DLI plasma. Microarray analysis revealed that >70% of the antigens were expressed in CML CD34+ cells, suggesting that expression in malignant progenitor cells is a feature common to antibody targets of DLI. We confirmed elevated expression of three target antigens (RAB38, TBCE, and DUSP12) in CML that together consistently elicited antibody responses in 18 of 21 of an additional cohort of CML patients with therapeutic responses, but not in normal donors and rarely in non-CML patients. In summary, immunologic targets of curative DLI responses include multiple antigens on CML progenitor cells, identifying them as potential immunogens for vaccination and/or monitoring of immunotherapeutics designed to eliminate myeloid leukemia stem cells.

Original languageEnglish
Pages (from-to)906-915
Number of pages10
JournalCancer Research
Volume70
Issue number3
DOIs
Publication statusPublished - Feb 1 2010
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Stem Cells
Tissue Donors
Antigens
Lymphocytes
Myeloid Leukemia
Therapeutics
Leukemia
B-Lymphocytes
Myeloid Progenitor Cells
Transplants
Lymphocytosis
Microarray Analysis
Antibody Formation
Immunoglobulins
Vaccination
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. / Biernacki, Melinda A.; Marina, Ovidiu; Zhang, Wandi; Liu, Fenglong; Bruns, Ingmar; Cai, Ann; Neuberg, Donna; Canning, Christine M.; Alyea, Edwin P.; Soiffer, Robert J.; Brusic, Vladimir; Ritz, Jerome; Wu, Catherine J.

In: Cancer Research, Vol. 70, No. 3, 01.02.2010, p. 906-915.

Research output: Contribution to journalArticle

Biernacki, MA, Marina, O, Zhang, W, Liu, F, Bruns, I, Cai, A, Neuberg, D, Canning, CM, Alyea, EP, Soiffer, RJ, Brusic, V, Ritz, J & Wu, CJ 2010, 'Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells', Cancer Research, vol. 70, no. 3, pp. 906-915. https://doi.org/10.1158/0008-5472.CAN-09-2303
Biernacki, Melinda A. ; Marina, Ovidiu ; Zhang, Wandi ; Liu, Fenglong ; Bruns, Ingmar ; Cai, Ann ; Neuberg, Donna ; Canning, Christine M. ; Alyea, Edwin P. ; Soiffer, Robert J. ; Brusic, Vladimir ; Ritz, Jerome ; Wu, Catherine J. / Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. In: Cancer Research. 2010 ; Vol. 70, No. 3. pp. 906-915.
@article{bd29a98279034e10b0de24566833cbbb,
title = "Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells",
abstract = "Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) may result from immunologic ablation of self-renewing CML progenitor cells. Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in patients who were unresponsive to DLI. In this study, we identified antigen targets of this B-cell response by probing two immunoproteomic platforms with plasma immunoglobulins from seven CML patients with clinically apparent graft-versus-leukemia responses after DLI. In total, 62 antigens elicited greater reactivity from post-DLI versus pre-DLI plasma. Microarray analysis revealed that >70{\%} of the antigens were expressed in CML CD34+ cells, suggesting that expression in malignant progenitor cells is a feature common to antibody targets of DLI. We confirmed elevated expression of three target antigens (RAB38, TBCE, and DUSP12) in CML that together consistently elicited antibody responses in 18 of 21 of an additional cohort of CML patients with therapeutic responses, but not in normal donors and rarely in non-CML patients. In summary, immunologic targets of curative DLI responses include multiple antigens on CML progenitor cells, identifying them as potential immunogens for vaccination and/or monitoring of immunotherapeutics designed to eliminate myeloid leukemia stem cells.",
author = "Biernacki, {Melinda A.} and Ovidiu Marina and Wandi Zhang and Fenglong Liu and Ingmar Bruns and Ann Cai and Donna Neuberg and Canning, {Christine M.} and Alyea, {Edwin P.} and Soiffer, {Robert J.} and Vladimir Brusic and Jerome Ritz and Wu, {Catherine J.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1158/0008-5472.CAN-09-2303",
language = "English",
volume = "70",
pages = "906--915",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells

AU - Biernacki, Melinda A.

AU - Marina, Ovidiu

AU - Zhang, Wandi

AU - Liu, Fenglong

AU - Bruns, Ingmar

AU - Cai, Ann

AU - Neuberg, Donna

AU - Canning, Christine M.

AU - Alyea, Edwin P.

AU - Soiffer, Robert J.

AU - Brusic, Vladimir

AU - Ritz, Jerome

AU - Wu, Catherine J.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) may result from immunologic ablation of self-renewing CML progenitor cells. Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in patients who were unresponsive to DLI. In this study, we identified antigen targets of this B-cell response by probing two immunoproteomic platforms with plasma immunoglobulins from seven CML patients with clinically apparent graft-versus-leukemia responses after DLI. In total, 62 antigens elicited greater reactivity from post-DLI versus pre-DLI plasma. Microarray analysis revealed that >70% of the antigens were expressed in CML CD34+ cells, suggesting that expression in malignant progenitor cells is a feature common to antibody targets of DLI. We confirmed elevated expression of three target antigens (RAB38, TBCE, and DUSP12) in CML that together consistently elicited antibody responses in 18 of 21 of an additional cohort of CML patients with therapeutic responses, but not in normal donors and rarely in non-CML patients. In summary, immunologic targets of curative DLI responses include multiple antigens on CML progenitor cells, identifying them as potential immunogens for vaccination and/or monitoring of immunotherapeutics designed to eliminate myeloid leukemia stem cells.

AB - Curative effects of graft-versus-leukemia-based therapies such as donor lymphocyte infusion (DLI) for chronic myelogenous leukemia (CML) may result from immunologic ablation of self-renewing CML progenitor cells. Patients who achieved durable remissions after DLI developed a significant B-cell lymphocytosis after treatment, which did not occur in patients who were unresponsive to DLI. In this study, we identified antigen targets of this B-cell response by probing two immunoproteomic platforms with plasma immunoglobulins from seven CML patients with clinically apparent graft-versus-leukemia responses after DLI. In total, 62 antigens elicited greater reactivity from post-DLI versus pre-DLI plasma. Microarray analysis revealed that >70% of the antigens were expressed in CML CD34+ cells, suggesting that expression in malignant progenitor cells is a feature common to antibody targets of DLI. We confirmed elevated expression of three target antigens (RAB38, TBCE, and DUSP12) in CML that together consistently elicited antibody responses in 18 of 21 of an additional cohort of CML patients with therapeutic responses, but not in normal donors and rarely in non-CML patients. In summary, immunologic targets of curative DLI responses include multiple antigens on CML progenitor cells, identifying them as potential immunogens for vaccination and/or monitoring of immunotherapeutics designed to eliminate myeloid leukemia stem cells.

UR - http://www.scopus.com/inward/record.url?scp=76249127539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249127539&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-2303

DO - 10.1158/0008-5472.CAN-09-2303

M3 - Article

VL - 70

SP - 906

EP - 915

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 3

ER -